MedTrace Logo

Effect of Adiponectin Genetic Polymorphism on Rosiglitazone Response

NCT00501488 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2007-07-20

No results posted yet for this study

Summary

The aims of the present study were to investigate the association between adiponectin gene polymorphisms and the response to rosiglitazone monotherapy in T2D patients.

A total of 255 T2D patients and 120 health volunteers were enrolled in this study. 42 T2D patients with -11377(C/G) or +45(T/G) genotypes were selected to administrate orally 4mg rosiglitazone daily for 12 consecutive weeks.

Conditions

Interventions

DRUG

rosiglitazone

Sponsors & Collaborators

  • Central South University

    lead OTHER

Principal Investigators

  • Zhao-Qian Liu, MD, Ph.D · Central South University Xiangya School of Medicine

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-03-31
Completion
2007-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00501488 on ClinicalTrials.gov